From 1996-2024, 82 cases of anaphylaxis associated with glatiramer acetate were reported to the FDA Adverse Event Reporting ...
The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment.
The US Food and Drug Administration (FDA) is adding the risk of anaphylaxis to a new boxed warning of glatiramer acetate, a ...
The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use ...
The FDA has advised health care professionals and patients with multiple sclerosis that treatment with glatiramer acetate is ...
The FDA added a boxed warning about rare cases of anaphylaxis associated with the multiple sclerosis (MS) drug glatiramer ...
On the basis of their well-established efficacy and tolerability profiles, IFNβ formulations and glatiramer acetate have been the mainstay of initial treatment for multiple sclerosis (MS ...
The drugs’ active ingredient, glatiramer acetate, has been linked to more than 80 cases of anaphylaxis worldwide since ...
FDA issues new warnings about rare but severe allergic reactions, including anaphylaxis, linked to MS drug glatiramer acetate, urging immediate medical attention.
The FDA is adding a new boxed warning to include information that anaphylaxis can occur at any time, from as early as after ...